SoftOx Solutions

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-18 am EDT			5-day change	1st Jan Change
0.21 ^NOK	-4.55%		-18.60%	-93.52%

Mar. 20	SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

SoftOx Solutions AS: Invitation to the presentation of the 4Q 2021 results

February 08, 2022 at 09:30 am EST

SoftOx Solution AS will be announcing its results for 4Q 2021 on Wednesday 16th
February 2022. A webcast presentation by the management will take place at 10:30
am CET.

Date: Wednesday, 16th February
Time: 10:30 - 11:30
RSVP: Registration to corporateaccess@sb1markets.no

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com

Click here for more information

Latest news about SoftOx Solutions

SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
SoftOx Solutions Seeks Extension of NOK40 Million Convertible Loan; Shares Jump	Jan. 16	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding	Jan. 10	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Oct. 31	CI
SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-26	CI
SoftOx Solutions Faces Penalty from Oslo Børs	23-09-18	MT
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-21	CI
SoftOx Solutions AS announced that it has received NOK 15 million in funding	23-06-08	CI
Oslo Børs Places Seven Issuers in Penalty Bench over Public Disclosure Rule Violations	23-06-02	MT
SoftOx Solutions Launches Temporary Layoffs Amid Restructuring; Shares Down 29%	23-03-27	MT
Softox Solutions AS Announces Resignation of Kari Myren from the Board	23-03-24	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Softox Solutions Announces Signing of the Final Grant Agreement for the Counteract Consortium	23-01-09	CI
SoftOx Solutions Appoints Interim CEO, New CFO	22-12-20	MT
SoftOx Solutions AS Appoints Christian Harstad as the Interim Chief Executive Officer	22-12-19	CI
SoftOx Solutions AS Announces Chief Financial Officer Changes	22-12-19	CI
Softox Solutions AS Announces Final Report Reaffirms Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	22-12-14	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26	CI
Softox Solutions Receives Swedish Approval For Disinfect Product	22-10-19	MT
Softox Solutions AS Announces Approval from the Swedish Chemicals Agency on Disinfection Products	22-10-18	CI
SoftOx Solutions Signs $2 Million Convertible Loan Deal, Secures Refinancing	22-10-11	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding from Aubert Invest AS, Pro AS, Almhaug Bolig AS and other investors	22-10-10	CI
SoftOx Solutions AS Announces Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	22-10-03	CI
SoftOx Solutions Completes Early-stage Trial for Treatment of Chronic Wounds; Shares Drop 6%	22-09-05	MT

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOx's product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOFTOX SOLUTIONS	-93.52%	9.59M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-0.44%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-7.45%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B